Drug Combination Details
| General Information of the Combination (ID: C49649) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Metastatic lymph node neoplasm
[ICD-11: 2D60]
|
Investigative | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
|
Laryngeal cancer
[ICD-11: 2C23]
|
Investigative | [3] | |||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [4] | |||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [5] | |||
|
Head and neck cancer
[ICD-11: 2D42]
|
Investigative | [6] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [7] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BAALC | Molecule Info | ||
| Down-regulation | Expression | NANOG | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SOX2 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H2170 | CVCL_1535 | Lung squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin significantly suppressed colonies formation and shrank the spheroids in CSC subpopulations when combined with cisplatin.This effect also was manifested by the down-regulation of SOX2, NANOG, and KLF4. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCG2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HEp-2 | CVCL_1906 | Laryngeal carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin enhances the effectiveness of cisplatin by suppressing CD133 + cancer stem cells in laryngeal carcinoma treatment. | |||||
| Experiment 2 Reporting the Effect of This Combination | [8] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | APAF1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H2170 | CVCL_1535 | Lung squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin enhanced the inhibitory effects of cisplatin on the highly migratory CD166+/EpCAM+ subpopulation. combined treatments induced cell cycle arrest, therefore triggering CSC growth inhibition via the intrinsic apoptotic pathway. | |||||
| Experiment 3 Reporting the Effect of This Combination | [9] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | ROS generation | ||||
| In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Co-treatment of the cells with curcumin and cisplatin resulted in increased apoptosis and reversal of Bcl-2-mediated cisplatin resistance. The mechanism by which curcumin down-regulates Bcl-2 and sensitizes cells to cisplatin-induced apoptosis involves proteasomal degradation of Bcl-2. | |||||
| Experiment 4 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | PE/CA-PJ49 | CVCL_2681 | Tongue squamous cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin acts against proliferation and sustain the effects of cisplatin by the induction of cell cycle arrest, amplification of DNA damage and contributing to cancer cell destruction by increasing the apoptotic process. Curcumin amplified the expression of P21 in tumor cells and might contribute to increasing the sensitivity to cisplatin. | |||||
| Experiment 5 Reporting the Effect of This Combination | [10] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CLU | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | HEp-2 | CVCL_1906 | Laryngeal carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Cisplatin-induced increases in mitochondrial ROS and cell death levels in Hep2 cells were further enhanced through the increase of TRPM2 activation with the effect of curcumin treatment. | |||||
| Experiment 6 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | FEN1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | The nude mice were anesthetized through isoflurane inhalation, and 1*107 MCF-7 cells suspending in 0.1 mL PBS was injected subcutaneously into the right axillary of each mouse. | |||||
| Experimental
Result(s) |
Curcumin sensitizes breast cancer cells to cisplatin through FEN1 down-regulation. Inhibiting ERK phosphorylation stimulated the chemosensitizing effect of curcumin to cisplatin by targeting FEN1. | |||||
| Experiment 7 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IKKB | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | NFKBIA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | CAL-27 | CVCL_1107 | Tongue squamous cell carcinoma | Homo sapiens | ||
| UM-SCC-1 | CVCL_7707 | Mouth squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | Five-week-old female athymic nude mice (nu/nu) were injected with 2*106 cells in the right flank to form xenograft tumors. | |||||
| Experimental
Result(s) |
Introduction of curcumin and suboptimal concentrations of cisplatin showed a significant suppressive effect compared with treatment with either agent alone. | |||||
| Experiment 8 Reporting the Effect of This Combination | [11] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | NOX5 | Molecule Info | ||
| In-vitro Model | HONE-1 | CVCL_8706 | Nasopharyngeal carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin enhances cisplatin sensitivity by suppressing NOX5 expression in human epithelial cancer. | |||||
| Experiment 9 Reporting the Effect of This Combination | [12] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | SLC31A1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| In-vivo Model | A549 cells or shCTR1 A549 cells were resuspended in ice cold serum-free medium (SFM) at 1*107/mL. The cells were mixed with equal volume of Matrigel. The cells (1*106/mouse) were implanted subcutaneously in the right flank near the rear leg of the mice under ketamine-xylazine anesthesia. | |||||
| Experimental
Result(s) |
Curcumin treatment enhances the binding of Sp1 to CTR1 and Sp1 promoters, thus induces CTR1 expression and chemosensitization to cisplatin treatment. This process is regulated by the Cu-Sp1-CTR1 regulatory loop and CTR1-dependent. | |||||
| Experiment 10 Reporting the Effect of This Combination | [13] | |||||
| Biological
Regulation |
Down-regulation | FANCD2 monoubiquitination | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
By suppressing the FA/BRCA pathway DNA repair, curcumin potentiates DDP-induced proliferation inhibitory effect and apoptosis in A549/DDP cell. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [14] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BDNF | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | PPAR-gamma | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Female Sprague-Dawley rats at the age of 8 weeks weighing 160-180 g were used in this study. | |||||
| Experimental
Result(s) |
Curcumin ameliorated cisplatin-induced nephrotoxicity and improved its anticancer activity in DMBA induced breast cancer in female Sprague-Dawley rats. | |||||
| γ. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | HIF-1A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combined curcumin and DDP treatment markedly inhibited A549/DDP cells proliferation, reversed cisplatin resistance and triggered apoptotic death by promoting HIF-1alpha degradation and activating caspase-3, respectively. | |||||
| Experiment 2 Reporting the Effect of This Combination | [5] | |||||
| In-vitro Model | HCT 8 | CVCL_2478 | Colon adenocarcinoma | Homo sapiens | ||
| In-vivo Model | HCT8/DDP cells (1*106) transfected with lenti-KCNQ1OT1 or lenti-NC were suspended in Matrigel matrix and subcutaneously injected into the back of male six-week-old nude mice. | |||||
| Experimental
Result(s) |
KCNQ1OT1 aggravated cisplatin resistance in CRC cells via the miR-497/Bcl-2 axis. | |||||
